December 9 | 2021 2cureX signs yet another distribution agreement – this time with Omnigen Medical Products in Turkey Read more
November 29 | 2021 EU publishes an article about the successful finalization of 2cureX’s MicroCaT project. Read more
November 25 | 2021 2cureX publishes interim report for the third quarter and first nine months of 2021 Read more
November 25 | 2021 2cureX offentliggör delårsrapport för det tredje kvartalet och första nio månader 2021 Read more
November 24 | 2021 2cureX expands its Clinical Advisory Board with Professor Andrew Beggs, Queen Elizabeth Hospital Birmingham, UK Read more
November 23 | 2021 2cureX holds a virtual live-session on the 26th of November 2021 to present and discuss the Interim report for the third quarter of 2021. Read more
October 29 | 2021 2cureX – Banbrytande cancerbehandlingstest rullas ut – Mangold Insight Analys Read more
October 15 | 2021 2cureX successfully completed the EU-project MicroCaT and received the final financial tranche of a 3,0 MEUR grant. Read more
October 12 | 2021 2cureX provides commercial goals for 2022 at Live Strategy Update on the 12th of October 2021. Read more
October 8 | 2021 2cureX provides a Live Strategy Update on the company’s product portfolio and commercialization strategy on the 12th of October 2021. Read more
September 28 | 2021 Specialized diagnostic solutions leader Werfen, to distribute 2cureX products in Spain Read more
August 26 | 2021 2cureX offentliggör delårsrapport för det andra kvartalet och första halvåret 2021 Read more
August 26 | 2021 2cureX publishes interim report for the second quarter and first half of 2021 Read more
August 20 | 2021 New development of the IndiTreat® technology allows prediction of response to anti-angiogenic drugs in colorectal cancer. Read more